Skip to main content

Thank you for visiting You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Volume 1 Issue 5, May 2020

Volume 1 Issue 5

Tracing the effects of tumor mutations on T cell differentiation

Characterizing the effects of tumor mutational burden on CD4+ and CD8+ T cell differentiation in non–small-cell lung cancer through the use of multi-omics.

See Ghorani et al.

Image: QuezadaLab, UCL Cancer Institute. Cover Design: Allen Beattie.


  • Editorial |

    The urgent need to address COVID-19 has highlighted the delicate relationships among science, politics and the media. To achieve a successful long-term response to the pandemic, stakeholders need to be guided by data, integrity and a sense of responsibility toward the public.

Comment & Opinion

  • Comment |

    Crowdsourcing efforts are currently underway to collect and analyze data from patients with cancer who are affected by the COVID-19 pandemic. These community-led initiatives will fill key knowledge gaps to tackle crucial clinical questions on the complexities of infection with the causative coronavirus SARS-Cov-2 in the large, heterogeneous group of vulnerable patients with cancer.

    • Aakash Desai
    • , Jeremy Warner
    •  & Gilberto Lopes

News & Views

  • News & Views |

    Studies of the tumor microenvironment have provided fundamental insights into cancer progression. A new study now delineates the dynamics of immune-cell alterations at the single-cell level and across stages of multiple myeloma, elucidating the microenvironmental changes involved in the precursor states of the disease.

    • Qiming Zhang
    •  & Zemin Zhang
  • News & Views |

    Immune-checkpoint blockade holds great promise in cancer therapy; however, T cell–specific checkpoint inhibitors are not effective for all patients with cancer. The transcription factor c-Rel is now shown to regulate pro-inflammatory polarization of myeloid cells and modulate anti-tumor immune responses.

    • Hideyuki Takahashi
    •  & Judy Varner


  • Review Article |

    Garnett and colleagues review principles that underpin the pre-clinical development of genomics-guided cancer medicines, challenges that limit their impact, and new opportunities, such as CRISPR-based screening, for refining and extending their use.

    • Hayley E. Francies
    • , Ultan McDermott
    •  & Mathew J. Garnett



Quick links